A case report of acquired hemophilia following COVID-19 vaccine

Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69-year-old gentleman who developed bleeding symptoms after receiving COVID-19 vaccine. Laboratory testing showed isolated prolongation of the activated partial thromboplastin time, and normal von Willebrand factor. Further testing confirmed the presence of factor VIII inhibitor. To date, no cases of AHA have been reported after exposure to COVID-19 vaccine. There have been two cases of AHA following seasonal flu and H1N1 vaccination, as well as two cases of AHA following COVID-19 infection. We present a summary of these cases and review of literature of autoimmune reactions following vaccination.

Automated summary

The report describes a 69-year-old man who developed Acquired Hemophilia A after receiving the COVID-19 vaccine, a rare occurrence. Other studies have also linked AHA to seasonal flu vaccines, H1N1 vaccines, and COVID-19 infection.